Follow: twitter LinkedIn facebook
Call Today: (617) 367-3311
Courtroom

Defective IVC Filters

Call Today: (617) 367-3311
Karon and Dalimonte, LLP, Attorneys at Law

Bard IVC Filters Discovered to Fracture and Migrate

Patients who suffer from the threat of pulmonary embolism and are contraindicated for anticoagulation therapy may find themselves receiving an Inferior Vena Cava filter or IVC to prevent pulmonary embolism.

Since the introduction of the IVC filter in 2005, the FDA has received roughly one thousand adverse reports involving these filters.  Specifically,  it was reported that the IVC filters fragment and embolize in the body. 

Research of these devices and the reports made by physicians and consumers has caused the FDA to urge physicians who advise their patients to use an IVC filter to consider the risk and benefits for individual patients instead of simply choosing the IVC for all patients who are ineligible for anticoagulation therapy, and to remove the device once the symptoms have diminished.

IVC filter complications are very serious and can be life threatening.  Out of the 921 reported events to the FDA, there were:

  • 328 device migrations
  • 146 involved embolizations or detachment of the device components
  • 70 IVC perforations
  • 56 IVC filter fractures

After reports that the radial arms and struts of the Bard Recovery IVC filter had broken off inside the body of patients in 2005, Bard attempted to modify this filter to correct this deadly defect.  The redesigned filter is the G2 IVC filter and has since been implanted in more than 65,000 patients.

According to reports posted on line, the November 8 print issue of the Archives of Internal Medicine, an archive journal of JAMA, is expected to publish a study conducted by William Nicholson M.D. and researchers from York Hospital in Pennsylvania concerning the safety of the implantation of Bard’s Peripheral Vascular Recovery and the G2 vena cava filters.  Specifically, the researchers examined the rate of complications after implantation of these IVC filters. 

Nicholson and his colleagues evaluated 189 patients with an implanted Bard Recovery or the Bard G2 vena cava filter between April 2004 and January 2009.  Among this group, 35 patients died, 10 already had their filter removed and one person was pregnant.  Eighty of these patients study underwent fluoroscopy to assess the integrity of the filter.  Patients who experienced any kind of fragmentation of the filter underwent echocardiography and cardiac CT.  Out of the 80 patients, 52 had the Bard redesigned G2 filter.

The Nicholson study found that 16 percent of the implanted filters fractured.  Associated with the original recovery filter, 25% fractured such that one or more arms of the filter device would break off.  Approximately 71% of the fragmented pieces would migrate through the veins of the patient to the heart, presenting life threatening symptoms such as rapid heartbeat and fluid buildup, including sudden death.

Despite the actions taken by Bard to redesign the original Recovery filter, the study has shown that 12 percent of the patients that had the G2 filter still experienced filter fractures. The average time the patients in the study had the implants was 50 months with the Recovery filter and 24 months with the G2 filter.



Contact Us

  1.  I have read and agree to the legal disclaimer and privacy policy




Legal Disclaimer
The material located on our web site is intended to be a resource for present and prospective clients. It is for informational purposes only and is not intended to be legal advice. The act of sending electronic mail to our firm or a specific attorney does not create an attorney-client relationship. This web site is not an offer to represent you. You should not act, or refrain from acting, based upon any information at this web site without seeking professional legal counsel. Under the rules of the Supreme Judicial Court of Massachusetts and other rules, this material may be considered advertising. The listing of areas of practice does not represent official certification of expertise therein.
Privacy Policy
This policy applies only to KDLaw.net and activities related to it, this policy does not necessarily apply to Karon & Dalimonte, LLP activities that are “offline” or unrelated to the Web site.

Visitors
All personal information that we might collect is protected by secured networks accessible only to our Webmaster and limited, necessary staff. Karon & Dalimonte, LLP as well as associated parties will never rent, sell, or reveal any collected personal information to persons or companies outside of our company without the visitor’s express permission, except to comply with the law where mandated. Like most corporate Web sites, KDLaw.net collects anonymous data about users to the site such as browser type, operating system, language, date & time of visit, and referring sites. We use this information to learn how visitors use the site and to influence site improvements. While KDLaw.net also collects some potentially identifying information such as Internet Protocol (IP) addresses, we do not use this information to identify visitors and we do not share this information externally except inline with any personal information collected as outlined above.

Other Websites
Karon & Dalimonte, LLP is not responsible for, and makes no recommendations on, the privacy policies for Web sites that are linked to from our pages.

Changes to this Policy
Karon & Dalimonte, LLP reserves the right to make changes to this statement of privacy. In such an event, any changes will be posted to this page and will take effect on the date on which they are posted. We encourage you to check back periodically. If you have any questions or wish to change any information received by Karon & Dalimonte, LLP, do not hesitate to use the contact form located on the Contact Page. Thank You